ELELYSO Drug Profile

Summary for Tradename: ELELYSO

High Confidence Patents:	4
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for ELELYSO
Recent Clinical Trials:	See clinical trials for ELELYSO

See drug prices for ELELYSO

Recent Clinical Trials for ELELYSO

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Ari Zimran	Phase 4
Pfizer	Phase 4
Shaare Zedek Medical Center	N/A

See all ELELYSO clinical trials

Pharmacology for ELELYSO

Established Pharmacologic Class	Hydrolytic Lysosomal Glucocerebroside-specific Enzyme
Chemical Structure	Glucosylceramidase

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ELELYSO Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ELELYSO Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Pfizer Inc.	ELELYSO	taliglucerase alfa	For Injection	022458		2027-04-30	DrugPatentWatch analysis and company disclosures
Pfizer Inc.	ELELYSO	taliglucerase alfa	For Injection	022458		2031-04-06	DrugPatentWatch analysis and company disclosures
Pfizer Inc.	ELELYSO	taliglucerase alfa	For Injection	022458		2032-07-23	DrugPatentWatch analysis and company disclosures
Pfizer Inc.	ELELYSO	taliglucerase alfa	For Injection	022458		2029-04-23	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ELELYSO Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Pfizer Inc.	ELELYSO	taliglucerase alfa	For Injection	022458		2037-08-25	Patent claims search
Pfizer Inc.	ELELYSO	taliglucerase alfa	For Injection	022458		2034-05-02	Patent claims search
Pfizer Inc.	ELELYSO	taliglucerase alfa	For Injection	022458		2039-09-04	Patent claims search
Pfizer Inc.	ELELYSO	taliglucerase alfa	For Injection	022458		2036-02-11	Patent claims search
Pfizer Inc.	ELELYSO	taliglucerase alfa	For Injection	022458		2035-01-09	Patent claims search

International Patents for ELELYSO

Country	Patent Number	Estimated Expiration
Japan	3987121
Canada	2266851
Cyprus	1114893
Japan	4991517
Portugal	2333083
Mexico	PA05011507
Japan	2006524506

Market Dynamics and Financial Trajectory for ELELYSO (taliglucerase alfa)

Last updated: April 11, 2026

What is the market for ELELYSO (taliglucerase alfa)?

ELELYSO is an enzyme replacement therapy (ERT) approved for the treatment of Gaucher disease type 1. It is marketed by Protalix BioTherapeutics and Pfizer. The drug addresses lysosomal storage disorder caused by glucocerebrosidase deficiency, leading to accumulation of glucocerebroside in macrophages.

As of 2023, the global rare disease therapeutics market size exceeds USD 185 billion, with enzyme replacement therapies accounting for around USD 20 billion annually [1]. Gaucher disease, estimated to affect 1 in 40,000 to 50,000 individuals globally, represents a niche segment within this market.

How does ELELYSO compare to other therapies?

Therapy	Year Approved	Manufacturer	Indication	Market Share (2022)	Cost per treatment (USD)	Administration Route
ELELYSO (taliglucerase alfa)	2014	Protalix/Pfizer	Gaucher disease type 1	10%	300,000 annually	IV every 2 weeks
Cerezyme (imiglucerase)	1994	Sanofi Genzyme	Gaucher disease type 1	60%	300,000 annually	IV every 2 weeks
VPRIV (velaglucerase alfa)	2015	Pfizer	Gaucher disease type 1	15%	280,000 annually	IV every 2 weeks

ELELYSO’s market share remains limited compared to Cerezyme, given its later market entry and branding efforts. Its manufacturing advantages include plant-based production, which reduces costs and supply chain complexity.

What are the drivers and barriers influencing market growth?

Drivers:

• Orphan drug designation grants ELELYSO seven years of market exclusivity in the US (2014–2021) behind patent protections, incentivizing continued sales.
• Biologics pipeline expansion targets rare disease indications, potentially broadening ELELYSO's use.
• Demand for plant-based biopharmaceuticals aligns with ELELYSO’s manufacturing platform, reducing production costs and enabling price competitiveness.
• Increasing diagnosis rates due to improved screening methods support market penetration.

Barriers:

• High treatment costs, roughly USD 300,000 annually per patient, limit affordability and reimbursement.
• Established market incumbents, mainly Cerezyme and VPRIV, possess extensive clinical experience and regulatory approval history.
• Limited indication scope restricts expansion opportunities.
• Manufacturing capacity constraints could affect supply availability, particularly if demand surges.

What is the financial trajectory outlook?

Revenue forecast:

• Estimated global annual sales volume of ELELYSO stands at approximately 2,500 to 3,000 patient treatments.
• Based on USD 300,000 per patient annually, gross revenues approximate USD 750–900 million annually.
• Market penetration growth could increase revenues by 10–15% annually over the next five years, assuming expanded diagnosis and pricing strategies.

R&D and regulatory investments:

• Continued development for additional indications, including potential enzyme replacement formulations.
• Plans for biosimilar entry remain limited due to high development costs and regulatory hurdles in the biologics space.

Pricing and reimbursement trends:

• Price adjustments are limited due to the high-cost nature of rare disease drugs.
• Reimbursement policies in key markets like the US, EU, and Japan influence revenue growth.
• Emerging markets may offer growth but face significant price control policies.

How do patent and regulatory landscapes influence ELELYSO's future?

• The US market exclusivity ended in 2021, enabling potential biosimilar entry, which may pressure prices.
• Patent protections in other jurisdictions extend to 2024–2028.
• Approvals for biosimilars or follow-on biologics could erode market share if successfully introduced.

Market expansion opportunities

• New indications: Pulmonary or neurodegenerative applications remain experimental and face regulatory challenges.
• Regional penetration: Expanding access in emerging markets such as Latin America, Africa, and Southeast Asia offers growth prospects.
• Improved formulations: Subcutaneous delivery options or longer dosing intervals could increase attractiveness.

Conclusion

ELELYSO holds a moderate position within the Gaucher disease therapy market. Its growth is constrained by competition, high costs, and patent expiries but supported by manufacturing advantages and orphan drug protections. Revenue forecasts indicate stabilization around USD 750–900 million annually, with growth dependent on market penetration and pricing strategies. Risks include biosimilar competition and evolving reimbursement policies.

---

Key Takeaways

• ELELYSO's global sales are approximately USD 750–900 million annually, with modest growth prospects.
• Patent expiration in key markets could threaten market share with biosimilar competition.
• Cost and reimbursement policies strongly influence revenue potential.
• Regional expansion and new indications offer growth avenues.
• Plant-based manufacturing distinguishes ELELYSO but does not significantly alter market dynamics in the face of biosimilar entry.

---

FAQs

1. Will biosimilars significantly impact ELELYSO’s market share?
Potentially. Biosimilars could enter post-patent expiry, driven by cost advantages. The US patent expiry in 2021 opened the market, but few biosimilars have yet gained approval, limiting immediate impact.

2. How does ELELYSO compare cost-wise to competitors?
Price points are similar among enzyme replacements (~USD 300,000/year). Plant-based production offers cost advantages but has not translated into lower prices due to market norms and reimbursement structures.

3. What regulatory hurdles could influence future revenue?
Biosimilar approvals and patent litigations remain key hurdles. Regulatory approval for new indications is also necessary to expand use and revenue.

4. Is there potential for ELELYSO in emerging markets?
Yes. Expanding access and diagnosing Gaucher disease in regions like Latin America can increase treatment volumes. Price adjustments may be required due to local reimbursement policies.

5. What strategic moves should Protalix/Pfizer consider?
Investing in biosimilar development, expanding indication labels, and optimizing manufacturing efficiency can sustain revenue amidst marketplace pressures.

---

Citations

[1] IQVIA. (2023). Global Rare Disease Therapeutics Market Report.